


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on January 14, 2004

Caroline Wei-Berk 45,203
Name of Attorney or Agent Registration No.

Signature of Attorney or Agent

P&G Case 8825MC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
John Severns et al. : Confirmation No. Not Yet Assigned
Serial No. Not Yet Assigned : Group Art Unit Not Yet Assigned
Filed January 14, 2004 : Examiner Not Yet Assigned

For Treatment of Fabric Articles with Specific Fabric Care Actives

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

3. 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1st O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.

(a) The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that both a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.

(b) The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed.

(c) The Notification of Acceptance of this Application Under 35 U.S.C. §371 does not indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.

4. 37 C.F.R. §1.97 (b)(4) - (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

5. Information to be Considered with CPA Filing. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

6. 37 C.F.R. §1.97(c) with fee payment - (use after 1st Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

(1) Copies of the cited references were previously cited by or submitted to the USPTO in prior application Case No. 8825M, U.S. Patent Application Serial No. 10/320,872 filed December 17, 2002. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).

OR

(2) Copies of the cited documents are enclosed.

OR

(3) Copies of all said documents, except document No.'s _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of document No.'s _____ are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of document No.'s _____ are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

(4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

(5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.

[] Additional information is attached.

Respectfully submitted,

By Caroline Wei-Berk
Caroline Wei-Berk
Attorney or Agent for Applicant(s)
Registration No. 45,203
(513) 627-0352

Date: January 14, 2004

Customer No. 27752

(IDS.doc)
(Last Revised 12/7/01)

COPENDING APPLICATIONS

Entire copies of all co-pending applications (or the portion of the application and claims that caused it to be cited) must be sent with the IDS (see 37 CFR 1.98(a)(2)(iii)

<u>Atty. Docket No.</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Filing Date</u>
8326	09/849,752	Severns	5/4/01
8327M	09/849,844	Severns	5/4/01
8708M	10/238,270	Anna Noyes	09/10/02
8826M	10/321,734	Scheper	12/17/02

[ones that are pending at time of this filing; others that have issued get cited on the PTO/SB08.]

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

SHEET 1 of 2

Application Number

Confirmation Number

Filing Date

January 14, 2004

First Named Inventor

John Severns et al.

Group Art Unit

Examiner Name

Attorney Docket Number

8825MC

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-4,659,332	12/13/2001	Hellsten et al.	
		US-4,102,824	07/25/1978	Mizutani Et al.	
		US-4,639,321	01/27/1987	Barrat et al.	
		US-4,685,930	08/11/1987	Kasprzak et al.	
		US-4,708,807	11/24/1987	Kemerer et al.	
		US-5,705,562	01/06/1998	Hill et al.	
		US-5,707,613	01/13/1998	Hill et al.	
		US-5,865,852	02/02/1999	Berndt et al.	
		US-5,876,510	03/02/1999	Kuemin et al.	
		US-5,888,250	03/30/1999	Hayday et al.	
		US-5,942,007	08/24/1999	Berndt et al.	
		US-5,977,040	11/02/1999	Inada et al.	
		US-5,985,810	11/16/1999	Inada et al.	
		US-6,013,683	01/11/2000	Hill et al.	
		US-6,042,617	03/28/2000	Berndt et al.	
		US-6042,618	03/28/2000	Berndt et al.	
		US-6,056,789	05/02/2000	Berndt et al.	
		US-6,059,845	05/09/2000	Berndt et al.	
		US-6,060,546	05/09/2000	Powell et al.	
		US-6,063,135	05/16/2000	Berndt et al.	
		US-6,136,766	10/24/2000	Inada et al.	
		US-6,156,074	12/5/2000	Hayday et al.	
		US-6,177,399	01/23/2001	Mei et al.	
		US-6,258,130 B1	07/10/2001	Murphy et al.	
		US-6,273,919 B1	08/14/2001	Hayday et al.	
		US-6,309,425 B1	10/30/2001	Murphy et al.	
		US-6,368,359	04/09/2002	Perry et al.	
		US20010020308	09/13/2001	Murphy et al.	
		US20010034912	11/01/2001	Kilgour et al.	
		US20020004953 A1	01/17/2002	Perry et al.	
		US20020115582	08/22/2002	Perry et al.	
		US20020174493	11/28/2002	Perry et al.	
		US-5,057,240	10/1991	Madore tal.	
		US 6,313,079	11/2001	Murphy	
		US 3,671,441	6/1972	Basch	
		US 6,200,352	03/2001	Romack	
		US 5,196,132	03/1993	Mains	
		US 6,310,029 B1	10/30/2001	Kilgour	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴				
		EP0982 023 A2		03/01/2000	General Electric Co.		
		EP 1 041 189 A1		10/04/2000	General Electric Co.		
		EP 1 043 443 A1		10/11/2000	General Electric Co.		
		EP 1092 803 A1		04/18/2001	Uniliver NV		
		DE 37 39 711 A1		06/08/1989	Chemische et al.		
		WO 00/04221		01/27/2000	Berndt et al.		
		WO 00/04222		01/27/2000	Greenearth Cleaning		
		WO 00/63340		10/26/2000	Dow Chemical et al.		
		WO 01/40567 A1		06/07/2001	Unilever et al.		
		WO 01/94678 A1		12/13/2001	Procter & Gamble		
		WO 01/94681 A1		12/13/2001	Procter & Gamble		
		WO 01/94684 A1		12/13/2001	Procter & Gamble		
		WO 02/46517 A1		06/13/2002	General Electric		
		WO 02/48447 A1		06/20/2002	General Electric		
		WO 02/50366 A1		06/27/2002	General Electric		
		WO 02/77356 A1		10/03/2002	General Electric		
		WO 02/97024		05/12/2002	Azuma et al.		
		JP 2000-290689		10/17/2000	Shin Etsu Chem et al.		
		WO 01/94521 A1		12/13/2001	Procter & Gamble		
		WO 01/94683 A1		12/13/2001	Procter & Gamble		
		WO 01/94685		12/13/2001	Procter & Gamble		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ⁶
		EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.